Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned ...

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; ...
The Lancet

A viral clonality evenness score to predict progression to adult T-cell leukaemia in asymptomatic carriers of human T-lymphotropic virus type 1 in Japan: a retr…

The implementation of VCE scoring in clinical practice could inform early pre-emptive therapeutic interventions, exclusively ...

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy ...